Literature DB >> 33287313

Modulation Effects of Toxoplasma gondii Histone H2A1 on Murine Macrophages and Encapsulation with Polymer as a Vaccine Candidate.

Zhengqing Yu1, Tianyuan Zhou1, Yanxin Luo1, Lu Dong1, Chunjing Li1, Junlong Liu2, Jianxun Luo2, Ruofeng Yan1, Lixin Xu1, Xiaokai Song1, Xiangrui Li1.   

Abstract

Toxoplasma gondii (T. gondii) is the most common zoonotic protozoa and has infected about one-third of the population worldwide. Recombinant epitopes encapsulated in nanospheres have advantages over traditional T. gondii vaccines. For an efficient delivery system, poly (DL-lactide-co-glycolide) (PLGA) and chitosan are the most frequently used biodegradable polymeric nanospheres with strong safety profiles. In the present study, we first expressed and purified histone H2A1 of T. gondii using the prokaryotic expression system. The effects of recombinant TgH2A1 on the functions of murine macrophages were then studied. Purified recombinant TgH2A1 was then encapsulated in nanospheres with PLGA and chitosan. After subcutaneous vaccination in mice, the immune response was evaluated by double antibody sandwich ELISA kits. The results from this study showed that PLGA and chitosan loaded with rTgH2A1 could trigger a stronger Th1 oriented immune response and prolong the survival time of mice effectively. In conclusion, PLGA and chitosan nanospheres loaded with histone H2A1 are an effective method for the development of vaccines against T. gondii. Further studies should focus on evaluating the regulatory mechanism of TgH2A1, vaccine potency, and cellular response in chronic T. gondii infections.

Entities:  

Keywords:  H2A1; PLGA; Toxoplasma gondii; chitosan; immune response; murine macrophage; nanoparticles

Year:  2020        PMID: 33287313     DOI: 10.3390/vaccines8040731

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN: 2076-393X


  2 in total

Review 1.  Advances in Toxoplasma gondii Vaccines: Current Strategies and Challenges for Vaccine Development.

Authors:  Ki-Back Chu; Fu-Shi Quan
Journal:  Vaccines (Basel)       Date:  2021-04-21

2.  Toxoplasma gondii Proteasome Subunit Alpha Type 1 with Chitosan: A Promising Alternative to Traditional Adjuvant.

Authors:  Zhengqing Yu; Wenxi Ding; Muhammad Tahir Aleem; Junzhi Su; Junlong Liu; Jianxun Luo; Ruofeng Yan; Lixin Xu; Xiaokai Song; Xiangrui Li
Journal:  Pharmaceutics       Date:  2021-05-19       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.